Looking forward to ASH 2017!
06 Dec 2017
The past year in the field of cellular immunotherapy in hematological malignancies has been extremely exciting. We saw FDA approval of the first CAR-T therapy for patients with ALL and then additional approvals for certain types of lymphoma. With several cellular immunotherapy products in development, it is indeed a thrilling time to be involved in the clinical trials of these novel therapies. At the annual American Society of Hematology conference this year, I am looking forward to learning more of recent advances, successes and challenges in developing these therapeutics as we all work together to overcome these hematological diseases that affect so many....Read post